季度财报
Fennec制药(FENC)05-15 05:35
$Fennec制药(FENC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-008162 Act: 34 Size: 6 MB 网页链接
简介:Fennec Pharmaceuticals Inc.最初是作为一家英属哥伦比亚公司成立的,其名称是“粘着”技术公司,随后于2014年9月3日改名。Fennec和它的全资子公司氧化奎特公司(“氧化物”)和Fennec制药公司,以及加拿大的一家加拿大公司(简称“CBI”),在这里被统称为“公司”,是一家生物制药公司,有一个正在开发中的产品,用于治疗癌症。该公司是一家生物制药公司,主要关注硫代硫酸钠(“STS”)的开发,以预防小儿癌症患者体内铂中毒的毒性。
今开:6.7 | 昨收:6.61 |
最高:6.7 | 最低:6.46 |
涨停价: | 跌停价: |
总市值:177867138 |
Fennec制药(FENC)05-15 05:35
$Fennec制药(FENC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-008162 Act: 34 Size: 6 MB 网页链接
Fennec制药(FENC)05-22 05:15
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-013982 Size: 9 KB 网页链接
Fennec制药(FENC)07-09 04:15
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019332 Size: 8 KB 网页链接
Fennec制药(FENC)06-26 04:15
$Fennec制药(FENC)$ 8-K Current report, item 5.07 Accession Number: 0001104659-24-074748 Act: 34 Size: 206 KB 网页链接
Fennec制药(FENC)07-03 04:15
$Fennec制药(FENC)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-005199 Act: 33 Size: 10 KB 网页链接
Fennec制药(FENC)06-04 05:15
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015177 Size: 6 KB 网页链接
Fennec制药(FENC)05-03 05:05
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012018 Size: 5 KB 网页链接
Fennec制药(FENC)05-02 04:15
$Fennec制药(FENC)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-003261 Act: 33 Size: 8 KB 网页链接
Fennec制药(FENC)05-14 04:45
$Fennec制药(FENC)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-007979 Act: 34 Size: 1 MB 网页链接
Fennec制药(FENC)05-22 05:15
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-013981 Size: 9 KB 网页链接
SeekingBiotech03-19 00:30
$Fennec制药(FENC)$
FENC announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI in Europe, Australia, and New Zealand. PEDMARQSI is an approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cispl...查看全文
薛定锷之猫2023-02-01 00:20
$Fennec制药(FENC)$ 会有公司收购它吗?If yes,收购价会是多少呢?
Part I:
1、 PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid ...查看全文
产业链观察2022-09-21 05:55
药闻▶$Fennec制药(FENC)$ 的Pedmark获得FDA批准,用于治疗有顺铂诱发耳毒性风险的儿科患者。查看全文
美股律师郝俊波2022-02-11 15:14
$Fennec制药(FENC)$ 【Fennec制药(FENC)最新证券集体诉讼】
Fennec Pharmaceuticals Inc(FENC)因证券欺诈案已经于近日被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司在2021年5月28日至 2021年11月26日期间(即本案集体诉讼期间)进行虚假陈述,违反证券法,令投资者受损。
Fenn...查看全文
chuminhua2021-11-30 10:47
11月29日,Fennec Pharmaceuticals 的股价周一下跌多达 48%,此前该公司表示预计将收到另一封针对其化疗引起的听力损失预防药物的完整回复函 (CRL)。 Fennec 正在寻求批准其名为 Pedmark 的硫代硫酸钠静脉制剂,以防止 1 个月至 18 岁的局部非转移性实体瘤患者与顺铂化疗相关的耳毒性。
根据 F...查看全文
美股律师郝俊波2020-08-18 11:29
$Fennec制药(FENC)$ 2020年8月11日Fennec Pharmaceuticals Inc(NASDAQ: FENC)发布消息称收到美国药监局关于该公司正在申请上市的PEDMARK产品的调查函。该函中称药监局在对该产品评估后认为存在需要解决的问题。受此不利消息影响,该公司股价大跌34%令投资者受损。
我们律师在此提醒投资者注意...查看全文
美股马甲2020-08-11 23:58
$Fennec制药(FENC)$ 这么简单的生产是如何在CMC上出问题的?查看全文
打电话过来2020-08-11 20:33
有为的股价小宝石2020-07-09 23:43
$Fennec制药(FENC)$ 再次上车查看全文
有为的股价小宝石2020-06-29 22:10
$Fennec制药(FENC)$ 7.2进的9块清了涨太慢查看全文
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019332 Size: 8 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019002 Size: 6 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-018984 Size: 5 KB 网页链接
$Fennec制药(FENC)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-005199 Act: 33 Size: 10 KB 网页链接
$Fennec制药(FENC)$ 8-K Current report, items 5.02, 8.01, and 9.01 Accession Number: 0001104659-24-076936 Act: 34 Size: 271 KB 网页链接
$Fennec制药(FENC)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001493152-24-025449 Act: 34 Size: 162 KB 网页链接
$Fennec制药(FENC)$ 8-K Current report, item 5.07 Accession Number: 0001104659-24-074748 Act: 34 Size: 206 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015201 Size: 5 KB 网页链接
$Fennec制药(FENC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015177 Size: 6 KB 网页链接
$Fennec制药(FENC)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-004301 Act: 33 Size: 9 KB 网页链接